DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,206 | +3.1% | 20,984 | -0.3% | 2.76% | +6.3% |
| Q2 2023 | $5,051 | -4.9% | 21,044 | -0.1% | 2.59% | -5.9% |
| Q1 2023 | $5,309 | -5.2% | 21,065 | -0.1% | 2.75% | -5.2% |
| Q4 2022 | $5,598 | -99.9% | 21,090 | +0.3% | 2.90% | -4.9% |
| Q3 2022 | $5,431,000 | -3.0% | 21,025 | -4.8% | 3.06% | +2.0% |
| Q2 2022 | $5,599,000 | -13.6% | 22,085 | 0.0% | 2.99% | -4.9% |
| Q1 2022 | $6,478,000 | -11.0% | 22,085 | -0.1% | 3.15% | -9.2% |
| Q4 2021 | $7,277,000 | +4.3% | 22,118 | -3.5% | 3.47% | -3.6% |
| Q3 2021 | $6,980,000 | +7.5% | 22,928 | -5.2% | 3.60% | +3.8% |
| Q2 2021 | $6,492,000 | +19.0% | 24,191 | -0.2% | 3.47% | +12.6% |
| Q1 2021 | $5,456,000 | +1.2% | 24,241 | -0.1% | 3.08% | -5.2% |
| Q4 2020 | $5,389,000 | +3.2% | 24,261 | +0.1% | 3.25% | -8.8% |
| Q3 2020 | $5,220,000 | +21.8% | 24,241 | 0.0% | 3.56% | +8.0% |
| Q2 2020 | $4,287,000 | +30.0% | 24,241 | +1.7% | 3.30% | +11.8% |
| Q1 2020 | $3,298,000 | +26.4% | 23,826 | +40.1% | 2.95% | +29.1% |
| Q4 2019 | $2,610,000 | +7.0% | 17,006 | +0.7% | 2.29% | +0.6% |
| Q3 2019 | $2,440,000 | – | 16,896 | – | 2.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |